Connect Biopharma Holdings Ltd
No SEC Form 4 filings for $CNTB in the last 30 days.
See all $CNTB insider activity →HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying a 614.5% upside from the last close. The firm cited strong clinical data and upcoming regulatory milestones as key catalysts. Recent analyst price targets range from $5 to $7.
BTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.
Connect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CNTB (Connect Biopharma Holdings Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CNTB coverage spans market movers, financial news and technology.
Positive clinical data and upgraded price target suggest strong upside potential.
Analyst target cut and mixed Phase II data suggest weaker near‑term outlook.
Positive Phase 2 data is likely to lift the stock as investors price in potential Phase 3 advancement and milestone payments.
Positive efficacy and safety data are likely to drive the stock higher as investors price in a potential Phase 3 path.
Trial miss may pressure short‑term price; secondary endpoint could support future Phase 3 design.
AlphAI scores every news story that mentions CNTB with an AI model for sentiment and relevance, and aggregates insider trades from Connect Biopharma Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. maintained a Buy rating on Connect Biopharma Hldgs with a $7 price target, implying a 614.5% upside from the last close. The firm cited strong clinical data and upcoming regulatory milestones as key catalysts. Recent analyst price targets range from $5 to $7.
1 min readBTIG reduced its price target for Connect Biopharma (CNTB) to $5.00 from $10.00, maintaining a Buy rating. The stock is down 65% YTD. The company's Seabreeze STAT COPD trial met its primary endpoint, showing an 81% reduction in treatment failure rate. BTIG lowered success probabilities and pushed launch timelines to 2030. Other analysts have mixed reactions, with some reiterating Buy ratings and others adjusting targets.
2 min readConnect Biopharma (NASDAQ:CNTB) shares rose 25% after reporting positive Phase 2 trial results for rademikibart, a drug candidate for COPD. The study showed significant reductions in treatment failure, exacerbations, and hospitalizations compared to placebo. The company plans to discuss a Phase 3 program with the FDA and may receive up to $99 million in milestone payments from Simcere Pharmaceutical.
2 min readConnect Biopharma (CNTB) reported positive Phase 2 data for rademikibart, showing an 81% reduction in treatment failure and 85% fewer new COPD exacerbations vs. placebo. The drug also eliminated hospitalizations/ED visits. The company plans to discuss the results with the FDA and host a conference call today.
2 min readConnect Biopharma (CNTB) reported mixed Phase 2 asthma trial results. Rademikibart missed the primary endpoint (p=0.153) but showed lung-function improvement (p=0.023). The company plans to use this measure in Phase 3. CNTB has $31.5M in cash but faces development costs. FDA feedback and funding are key uncertainties.
2 min readConnect Biopharma's stock fell 33.6% to $1.145 after its Phase 2 asthma drug trial failed to meet the primary endpoint, despite showing some positive results. The company's drug, rademikibart, did not achieve statistical significance in reducing treatment failure rates. Analysts had previously set a $7.00 price target. The broader market also declined slightly.
2 min readModular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
3 min readConnect Biopharma Holdings Ltd (CNTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update – Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT stud
5 min readBiotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.
6 min readConnect Biopharma (Nasdaq: CNTB) said it has completed enrollment in its Phase 2 Seabreeze STAT Asthma study of rademikibart (adjunct to standard of care) for acute asthma exacerbations in patients with type 2 inflammation; it enrolled 160 participants. The company expects topline data in early September 2026, plans to complete COPD enrollment this month, and aims to align on a Phase 3 program with the FDA later this year.
4 min read
